15 assets in Intravascular Large B-Cell Lymphoma

Therapeutic assets addressing Intravascular Large B-Cell Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Vincristine Sulfate Intravascular Large B-Cell Lymphoma	Northwestern University	P2/3	BB (68)
Adriamycin Intravascular Large B-Cell Lymphoma	Northwestern University	P2/3	BB (67)
Prednisone Intravascular Large B-Cell Lymphoma	Northwestern University	P2/3	BB (67)
Cyclophosphamide Intravascular Large B-Cell Lymphoma	Mayo Clinic	P2/3	BB (66)
Rituximab Intravascular Large B-Cell Lymphoma	Mayo Clinic	P2/3	BB (66)
Nivolumab Intravascular Large B-Cell Lymphoma	National Cancer Institute (NCI)	P2	B (60)
Azacitidine Intravascular Large B-Cell Lymphoma	National Cancer Institute (NCI)	P2/3	B (57)
Recombinant Human Hyaluronidase Intravascular Large B-Cell Lymphoma	National Cancer Institute (NCI)	P2/3	B (57)
Epirubicin Intravascular Large B-Cell Lymphoma	Mayo Clinic	P2	CCC (53)
Golcadomide Intravascular Large B-Cell Lymphoma	Mayo Clinic	P2	CCC (53)
Ontorpacept Intravascular Large B-Cell Lymphoma	Mayo Clinic	P2	CCC (53)
Pembrolizumab Intravascular Large B-Cell Lymphoma	Mayo Clinic	P2	CCC (53)
Zanubrutinib Intravascular Large B-Cell Lymphoma	Northwestern University	P2	CCC (53)
1-118-Signal regulatory protein ? (human) fusion protein with immunoglobulin G4 [128-proline] (human ?4-chain C region C-terminal fragment), dimer Intravascular Large B-Cell Lymphoma	Mayo Clinic	P2	CC (45)
Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer Intravascular Large B-Cell Lymphoma	National Cancer Institute (NCI)	P2	CC (44)